For the past two years, we have been witnessing how important it is for countries to have their own developed biopharmaceutical industry and science. With global shortage of industrial capacity for vaccine production, many countries have become dependent on foreign manufacturers. In recent years, the Russian regulatory system has been improving, programmes are being implemented to support domestic biopharmaceutical production and high-tech technologies, which ultimately made it possible to effectively respond to the main challenge of the times and develop new vaccines against COVID-19.
Our company was established by Rostec State Corporation, which focuses on security issues, including national health issues as a response to the public need to ensure independence in domestic production of biological products and, above all, vaccines. For more than five years, we have been managing Russian developers and manufacturers of immunobiological drugs assigned to the holding, during which time we have achieved significant success in specific segments − in particular, in the fill-finish production of influenza vaccines, as well as a number of live and specific vaccines. Today, their share in government vaccination programmes has reached 100%, and, no doubt, this is also the result of a synergy between business and the government.
It is important to note that not a single successful project related to providing citizens with affordable and effective drugs is born all by itself, it always results from a dialogue between the expert community, business, legislation, and executive authorities, including at industry events. The International GMP Conference is one of the influential platforms focusing on the key problems and challenges of the pharmaceutical industry development.
Our company has participated in the Conference for several years, and we give credit to the organisers for creating positive atmosphere, working out an informative agenda and raising the issues topical for the industry, thereby contributing to the implementation of key initiatives and projects in practice.
We wish the guests and organisers of the Conference fruitful work.
Andrey Zagorsky, General Director of Nacimbio